MedStar Authors catalog › Details for: Antiplatelet and anticoagulation regimen in patients with mechanical valve undergoing PCI - State-of-the-art review.
Normal view MARC view ISBD view

Antiplatelet and anticoagulation regimen in patients with mechanical valve undergoing PCI - State-of-the-art review.

by Gajanana, Deepakraj; Rogers, Toby; Iantorno, Micaela; Buchanan, Kyle; Ben-Dor, Itsik; Pichard, Augusto D; Satler, Lowell F; Torguson, Rebecca; Okubagzi, Petros; Waksman, Ron.
Citation: International Journal of Cardiology. 264:39-44, 2018 08 01..Journal: International journal of cardiology.Published: 2018ISSN: 0167-5273.Full author list: Gajanana D; Rogers T; Iantorno M; Buchanan KD; Ben-Dor I; Pichard AD; Satler LF; Torguson R; Okubagzi PG; Waksman R.UI/PMID: 29685692.Subject(s): Anticoagulants/ad [Administration & Dosage] | Anticoagulants/ae [Adverse Effects] | *Anticoagulants | Drug Therapy, Combination/ae [Adverse Effects] | Drug Therapy, Combination/mt [Methods] | *Drug Therapy, Combination | Heart Valve Prosthesis/cl [Classification] | Heart Valve Prosthesis/st [Standards] | *Heart Valve Prosthesis | Hemorrhage/ci [Chemically Induced] | Hemorrhage/pc [Prevention & Control] | *Hemorrhage | Humans | *Percutaneous Coronary Intervention/mt [Methods] | Platelet Aggregation Inhibitors/ad [Administration & Dosage] | Platelet Aggregation Inhibitors/ae [Adverse Effects] | *Platelet Aggregation Inhibitors | Purinergic P2Y Receptor Antagonists/ad [Administration & Dosage] | Purinergic P2Y Receptor Antagonists/ae [Adverse Effects] | *Purinergic P2Y Receptor Antagonists | Risk AdjustmentInstitution(s): MedStar Heart & Vascular InstituteActivity type: Journal Article.Medline article type(s): Journal ArticleDigital Object Identifier: (Click here) Abbreviated citation: Int J Cardiol. 264:39-44, 2018 08 01.Abstract: A common clinical dilemma regarding treatment of patients with a mechanical valve is the need for concomitant antiplatelet therapy for a variety of reasons, referred to as triple therapy. Triple therapy is when a patient is prescribed aspirin, a P2Y12 antagonist, and an oral anticoagulant. Based on the totality of the available evidence, best practice in 2017 for patients with mechanical valves undergoing percutaneous coronary intervention (PCI) is unclear. Furthermore, the optimal duration of dual antiplatelet therapy after PCI is evolving. With better valve designs that are less thrombogenic, the thromboembolic risks can be reduced at a lower international normalized ratio target, thus decreasing the bleeding risk. This review will offer an in-depth survey of current guidelines, current evidence, suggested approach for PCI in this cohort, and future studies regarding mechanical valve patients undergoing PCI.Abstract: Copyright (c) 2017 Elsevier B.V. All rights reserved.

Powered by Koha